WuXi Biologics Celebrates Inclusion in S&P Global Sustainability Yearbook 2025
WuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced its inclusion in the S&P Global Sustainability Yearbook 2025. This recognition is a testament to its exceptional sustainability performance throughout the previous year. WuXi Bio, marked by its stock code 2269.HK, has successfully ranked in the top 1% of the S&P Global Corporate Sustainability Assessment (CSA). This is not just a singular achievement; it is the third consecutive year that WuXi Biologics has earned such prestigious acknowledgment.
The S&P Global Sustainability Yearbook serves as a benchmark for corporate sustainability across various sectors. Companies are selected based on their S&P Global CSA scores, which comprehensively evaluate their sustainability practices. In the latest assessment, out of 7,690 companies evaluated in 2024, only 780 made it to the elite list for inclusion in the Yearbook 2025.
The Commitment to Sustainability
Dr. Chris Chen, serving as CEO of WuXi Biologics and the Chairman of its ESG Committee, expressed pride in this recognition. He stated, "We are very pleased to be once again selected for inclusion in the Yearbook, a reflection of our steadfast dedication to enhancing our sustainability performance." WuXi Biologics is not only known for its operational excellence but also for its commitment to environmental, social, and governance (ESG) principles. They aim to lead the green CRDMO sector by promoting innovative practices that contribute to a healthier future.
WuXi Biologics has consistently engaged in sustainable development initiatives. Over the last few years, the company has received accolades from the Dow Jones Sustainability Indices for 2023 and 2024 due to its ongoing efforts in advocating sustainability. Moreover, as a participant in the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative, WuXi Biologics plays an integral role in sustainability dialogues on a global scale.
A Series of Notable Accolades
This year, WuXi Biologics has garnered numerous honors that highlight its dedication to sustainability. The company has been awarded an MSCI AAA Rating, recognizing it as a leader in ESG performance. Additionally, WuXi has received the EcoVadis Platinum Medal for two consecutive years. Its contributions to sustainable development have also been highlighted in the UNGC 20 Case Examples, demonstrating their leadership in delivering green biologics solutions.
Further accolades include being recognized as a Sustainalytics top-rated company for five years in a row, being listed on the CDP Water Security "A List," and earning an "A-" CDP Climate Change score. WuXi Biologics has made a mark by being included in the FTSE4Good Index Series and the Hang Seng ESG 50 Index, showcasing its robust commitment to sustainable practices in the life sciences sector.
About WuXi Biologics
WuXi Biologics stands at the forefront of biopharmaceutical development and manufacturing. With a workforce exceeding 12,000 across multiple global locations including China, the United States, Ireland, Germany, and Singapore, it provides comprehensive solutions designed to enhance the biopharmaceutical pipeline. By simplifying the process from concept to commercialization, WuXi Biologics alleviates the complexities faced by its partners, thus fostering the development of biologics that benefit patients worldwide.
The company is currently managing 817 active client projects, which include 21 in commercial manufacturing operations, excluding COVID-related projects. This is indicative of the trust and reliance that clients place in WuXi Biologics' expertise and capabilities.
WuXi Biologics has woven ESG responsibilities into its core strategy, viewing these commitments as fundamental to its operations. It utilizes innovative biomanufacturing techniques powered by clean energy sources, and it has established a dedicated ESG committee led by the CEO to refine and implement its sustainability strategies.
To learn more about WuXi Biologics and its impactful contributions to the industry, interested parties are encouraged to find more information online.
Frequently Asked Questions
What is WuXi Biologics' recent achievement?
WuXi Biologics has been included in the S&P Global Sustainability Yearbook 2025 for its remarkable sustainability performance.
How does WuXi Biologics rank in sustainability?
WuXi Biologics ranks in the top 1% of the S&P Global Corporate Sustainability Assessment, showcasing its commitment to sustainable practices.
How many years has WuXi Biologics received this recognition?
This marks the third consecutive year that WuXi Biologics has been included in the S&P Global Sustainability Yearbook.
What does WuXi Biologics do?
WuXi Biologics provides end-to-end contract research, development, and manufacturing services for biologics, from concept to commercialization.
Where does WuXi Biologics operate?
WuXi Biologics operates in several countries, including China, the United States, Ireland, Germany, and Singapore, employing over 12,000 skilled employees.
